Atrialfibrillation Supraventricular tachycardia
Conditions
Interventions
- 1:1 randomization to a lower rate of DDDR 80 bpm (intervention) or a lower
rate of DDDR 60 bpm (control). Duration of the study is 6 months.
In a subset of participants:
- Right heart catheterisa
Sponsors
Maastricht Universitair Medisch Centrum +
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Adults >18 years of age Referred for AVNA as part of an pace-and-ablate strategy with LBBAP for symptomatic AF symptomatic AF Left ventricular ejection fraction >40% Willingness to participate, to understand the intructions and fill out the questionnaires
Exclusion criteria
Exclusion criteria: Infiltrative or constrictive cardiomyopathy Severe valvular heart disease Participation in another interventional clinical trial recent myocardial infacrtion, Transient Ischemic Attack, Cerebro-vascular accident
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in HRQoL between a lower rate of 80 bpm and a lower rate of 60 bpm, based on the Minnesota Living with Heart Failure Questionnaire (MLHFQ), determined at 6 months follow-up. | — |
Secondary
| Measure | Time frame |
|---|---|
| - The acute hemodynamic effects of (accelerated) pacing at time of AVNA: o Pulmonary Capillary Wedge Pressure (PCWP) o Cardiac Output (CO) o Systemic arterial blood pressure - The long-term effect of accelerated pacing on: o HRQoL, based on the MLHFQ and SF-36 questionnaires. o NT-proBNP levels o Device detected AF burden o Device detected daily activity comparing accelerated- vs control rate o Echocardiographic measurements (LVEF, LVEDD, LVESD, LAVI, LA strain) - Symptoms experienced as a result of (accelerated) pacing based on the AFEQT questionnaire | — |
Countries
Canada, Netherlands
Contacts
Public ContactJ Koll
Maastricht Universitair Medisch Centrum +
Outcome results
None listed